Qulipta Archives -

AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to

AbbVie files Qulipta for chronic migraine prevention

https://pharmaphorum.com/news/abbvie-files-qulipta-for-chronic-migraine-prevention/

Pfizer’s $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff

Pfizer/Biohaven migraine drug rimegepant gets EU green light

https://pharmaphorum.com/news/pfizer-biohaven-migraine-drug-rimegepant-gets-eu-green-light/

AbbVie’s Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic

AbbVie sees bigger role for Qulipta in migraine prevention

https://pharmaphorum.com/news/abbvie-sees-bigger-role-for-qulipta-in-migraine-prevention/

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for

AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

https://pharmaphorum.com/news/abbvies-qulipta-cleared-for-migraine-prevention-setting-up-biohaven-clash/

Qulipta